Select Publications
Journal articles
2023, '1127P Efficacy of immune checkpoint inhibitors (ICIs) in advanced mucosal melanoma (MM): A systematic review and meta-analysis', Annals of Oncology, 34, pp. S677 - S677, http://dx.doi.org/10.1016/j.annonc.2023.09.2261
,2023, '1825P Molecular features of circulating tumour cells (CTCs) associate with response to 177Lu-PSMA-617 plus pembrolizumab for metastatic castration resistant prostate cancer (mCRPC)', Annals of Oncology, 34, pp. S988 - S989, http://dx.doi.org/10.1016/j.annonc.2023.09.2773
,2023, '1831P Dissecting the meaning of obesity in metastatic castration resistant prostate cancer: Size or metabolism?', Annals of Oncology, 34, pp. S991 - S991, http://dx.doi.org/10.1016/j.annonc.2023.09.2779
,2023, '1886P Pembrolizumab and denosumab in clear cell renal cell carcinoma (ccRCC): A phase II trial (KeyPAD, ANZUP1601)', Annals of Oncology, 34, pp. S1014 - S1014, http://dx.doi.org/10.1016/j.annonc.2023.09.1116
,2023, 'Integrated, Longitudinal Analysis of Cell-free DNA in Uveal Melanoma.', Cancer Res Commun, 3, pp. 267 - 280, http://dx.doi.org/10.1158/2767-9764.CRC-22-0456
,2023, 'LBA50 Three-year survival with tebentafusp in previously untreated metastatic uveal melanoma in a phase III trial', Annals of Oncology, 34, pp. S1289 - S1290, http://dx.doi.org/10.1016/j.annonc.2023.10.044
,2023, 'LBA84 Enzalutamide and 177Lu-PSMA-617 in poor-risk, metastatic, castration-resistant prostate cancer (mCRPC): A randomised, phase II trial: ENZA-p (ANZUP 1901)', Annals of Oncology, 34, pp. S1325 - S1325, http://dx.doi.org/10.1016/j.annonc.2023.10.086
,2022, 'Combined impact of lipidomic and genetic aberrations on clinical outcomes in metastatic castration-resistant prostate cancer', BMC Medicine, 20, http://dx.doi.org/10.1186/s12916-022-02298-0
,2022, 'The cell-free DNA methylome captures distinctions between localized and metastatic prostate tumors', Nature Communications, 13, http://dx.doi.org/10.1038/s41467-022-34012-2
,2022, 'PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial', The Lancet Oncology, 23, pp. 1389 - 1397, http://dx.doi.org/10.1016/S1470-2045(22)00605-2
,2022, 'Modulation of Plasma Lipidomic Profiles in Metastatic Castration-Resistant Prostate Cancer by Simvastatin', Cancers, 14, http://dx.doi.org/10.3390/cancers14194792
,2022, 'BRAF inhibition and the spectrum of granulomatous reactions', Journal of the American Academy of Dermatology, 87, pp. 605 - 613, http://dx.doi.org/10.1016/j.jaad.2021.10.030
,2022, 'A review of the cutaneous toxicities of tebentafusp—Featuring two cases involving superficial bullous reactions', Australasian Journal of Dermatology, 63, pp. e279 - e282, http://dx.doi.org/10.1111/ajd.13866
,2022, 'A novel methylated cell-free DNA marker panel to monitor treatment response in metastatic prostate cancer', Epigenomics, 14, pp. 811 - 822, http://dx.doi.org/10.2217/epi-2022-0103
,2022, 'Effects of metformin and statins on outcomes in men with castration-resistant metastatic prostate cancer: Secondary analysis of COU-AA-301 and COU-AA-302', European Journal of Cancer, 170, pp. 296 - 304, http://dx.doi.org/10.1016/j.ejca.2022.03.042
,2022, 'Pembrolizumab Plus Docetaxel and Prednisone in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort B Study', European Urology, 82, pp. 22 - 30, http://dx.doi.org/10.1016/j.eururo.2022.02.023
,2022, 'Statin and metformin use and outcomes in patients with castration-resistant prostate cancer treated with enzalutamide: A meta-analysis of AFFIRM, PREVAIL and PROSPER', European Journal of Cancer, 170, pp. 285 - 295, http://dx.doi.org/10.1016/j.ejca.2022.04.005
,2022, 'Clinical trials for metastatic castrate-resistant prostate cancer—who is looking after the control patients? Questions for the future', Annals of Oncology, 33, pp. 574 - 577, http://dx.doi.org/10.1016/j.annonc.2022.03.272
,2022, 'Dual checkpoint targeting of B7-H3 and PD-1 with enoblituzumab and pembrolizumab in advanced solid tumors: Interim results from a multicenter phase I/II trial', Journal for ImmunoTherapy of Cancer, 10, http://dx.doi.org/10.1136/jitc-2021-004424
,2022, '177Lu-PSMA-617 and Idronoxil in Men with End-Stage Metastatic Castration-Resistant Prostate Cancer (LuPIN): Patient Outcomes and Predictors of Treatment Response in a Phase I/II Trial', Journal of Nuclear Medicine, 63, pp. 560 - 566, http://dx.doi.org/10.2967/jnumed.121.262552
,2022, 'Health-Related Quality of Life in Metastatic, Hormone-Sensitive Prostate Cancer: ENZAMET (ANZUP 1304), an International, Randomized Phase III Trial Led by ANZUP', Journal of Clinical Oncology, 40, pp. 837 - 846, http://dx.doi.org/10.1200/JCO.21.00941
,2022, 'Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial', The Lancet Oncology, 23, pp. 362 - 373, http://dx.doi.org/10.1016/S1470-2045(21)00757-9
,2022, 'Patient Preference or Indifference: Learning from the CABADOC Study', European Urology, 81, pp. 241 - 242, http://dx.doi.org/10.1016/j.eururo.2021.11.005
,2022, 'Expansion of Lymphocytes from Prostatic Adenocarcinoma and Adjacent Nonmalignant Tissue', Prostate Cancer, 2022, http://dx.doi.org/10.1155/2022/6499344
,2022, 'KEYNOTE-022: Pembrolizumab with trametinib in patients with BRAF wild-type melanoma or advanced solid tumours irrespective of BRAF mutation', European Journal of Cancer, 160, pp. 1 - 11, http://dx.doi.org/10.1016/j.ejca.2021.09.024
,2022, 'Radiographic progression-free survival in the ACIS trial for prostate cancer', The Lancet Oncology, 23, pp. e4, http://dx.doi.org/10.1016/S1470-2045(21)00719-1
,2022, '1389P Two-year follow-up of KEYNOTE-365 cohort D: Pembrolizumab (pembro) plus abiraterone acetate (abi) and prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC)', Annals of Oncology, 33, pp. S1178 - S1178, http://dx.doi.org/10.1016/j.annonc.2022.07.1521
,2022, '1403P Efficacy and safety of dendrimer-enhanced (DEP) cabazitaxel (CTX-SPL9111) in men with metastatic castration-resistant prostate cancer (mCRPC) in a phase I/II trial', Annals of Oncology, 33, pp. S1186 - S1187, http://dx.doi.org/10.1016/j.annonc.2022.07.1889
,2022, '821P Safety and efficacy of infrequent tebentafusp treatment omissions in patients with metastatic uveal melanoma', Annals of Oncology, 33, pp. S923 - S923, http://dx.doi.org/10.1016/j.annonc.2022.07.947
,2022, 'EP16.03-041 Single Cell RNA Sequencing Reveals Phenotypic Predispositions to Developing Lung Cancer in Never-Smokers', Journal of Thoracic Oncology, 17, pp. S608 - S608, http://dx.doi.org/10.1016/j.jtho.2022.07.1102
,2022, 'Repurposing Itraconazole and Hydroxychloroquine to Target Lysosomal Homeostasis in Epithelial Ovarian Cancer.', Cancer Res Commun, 2, pp. 293 - 306, http://dx.doi.org/10.1158/2767-9764.CRC-22-0037
,2021, 'Barriers and facilitators related to undertaking physical activities among men with prostate cancer: a scoping review', Prostate Cancer and Prostatic Diseases, 24, pp. 1007 - 1027, http://dx.doi.org/10.1038/s41391-021-00399-0
,2021, 'Cryopreservation of human cancers conserves tumour heterogeneity for single-cell multi-omics analysis', Genome Medicine, 13, http://dx.doi.org/10.1186/s13073-021-00885-z
,2021, 'Cutaneous sarcoidosis due to immune-checkpoint inhibition and exacerbated by a novel BRAF dimerization inhibitor', Skin Health and Disease, 1, http://dx.doi.org/10.1002/ski2.71
,2021, 'Phase I/II Trial of the Combination of 177Lutetium Prostate specific Membrane Antigen 617 and Idronoxil (NOX66) in Men with End-stage Metastatic Castration-resistant Prostate Cancer (LuPIN)', European urology oncology, 4, pp. 963 - 970, http://dx.doi.org/10.1016/j.euo.2020.07.002
,2021, 'Re: Overall Survival of Men with Metachronous Metastatic Hormone-Sensitive Prostate Cancer Treated with Enzalutamide and Androgen Deprivation Therapy', JOURNAL OF UROLOGY, 206, pp. 1519 - 1520, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000716572000083&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2021, 'ENZA-p trial protocol: a randomized phase II trial using prostate-specific membrane antigen as a therapeutic target and prognostic indicator in men with metastatic castration-resistant prostate cancer treated with enzalutamide (ANZUP 1901)', BJU International, 128, pp. 642 - 651, http://dx.doi.org/10.1111/bju.15491
,2021, 'Long-term outcomes in patients with advanced melanoma who had initial stable disease with pembrolizumab in KEYNOTE-001 and KEYNOTE-006', European Journal of Cancer, 157, pp. 391 - 402, http://dx.doi.org/10.1016/j.ejca.2021.08.013
,2021, 'Overcoming enzalutamide resistance in metastatic prostate cancer by targeting sphingosine kinase', EBioMedicine, 72, http://dx.doi.org/10.1016/j.ebiom.2021.103625
,2021, 'Real-world use of first-generation antiandrogens: impact on patient outcomes and subsequent therapies in metastatic castration-resistant prostate cancer', BJU International, 128, pp. 18 - 26, http://dx.doi.org/10.1111/bju.15364
,2021, 'Relationship between circulating lipids and cytokines in metastatic castration‐resistant prostate cancer', Cancers, 13, http://dx.doi.org/10.3390/cancers13194964
,2021, 'Overall survival benefit with tebentafusp in metastatic uveal melanoma', New England Journal of Medicine, 385, pp. 1196 - 1206, http://dx.doi.org/10.1056/NEJMoa2103485
,2021, 'Health-related quality of life (HRQoL) at final analysis of the GALAHAD study of niraparib in patients with metastatic castration-resistant prostate cancer (mCRPC) and DNA repair defects (DRD)', ANNALS OF ONCOLOGY, 32, pp. S632 - S633, http://dx.doi.org/10.1016/j.annonc.2021.08.1095
,2021, 'KEYNOTE-365 cohort I: Phase Ib/II study of platinum containing chemotherapy in combination with pembrolizumab and chemotherapy alone for treatment-emergent neuroendocrine prostate carcinoma (t-NE)', ANNALS OF ONCOLOGY, 32, pp. S669 - S669, http://dx.doi.org/10.1016/j.annonc.2021.08.1152
,2021, 'Phase Ib/II trial of pembrolizumab (pembro) plus lenvatinib combination therapy in patients (pts) with adenocarcinoma metastatic castration-resistant prostate cancer (mCRPC) or treatment-emergent neuroendocrine mCRPC (t-NE): KEYNOTE-365 cohorts E and F', ANNALS OF ONCOLOGY, 32, pp. S669 - S670, http://dx.doi.org/10.1016/j.annonc.2021.08.1153
,2021, 'Phase Ib/II trial of pembrolizumab (pembro) plus vibostolimab combination therapy in patients (Pts) with adenocarcinoma metastatic castration-resistant prostate cancer (mCRPC) or treatment-emergent neuroendocrine mCRPC (t-NE): KEYNOTE-365 cohorts G and H', ANNALS OF ONCOLOGY, 32, pp. S670 - S671, http://dx.doi.org/10.1016/j.annonc.2021.08.1154
,2021, 'Overall Survival of Men with Metachronous Metastatic Hormone-sensitive Prostate Cancer Treated with Enzalutamide and Androgen Deprivation Therapy', European Urology, 80, pp. 275 - 279, http://dx.doi.org/10.1016/j.eururo.2021.05.016
,2021, 'Parp inhibitors in melanoma—an expanding therapeutic option?', Cancers, 13, http://dx.doi.org/10.3390/cancers13184520
,2021, 'UpFrontPSMA: a randomized phase 2 study of sequential 177Lu-PSMA-617 and docetaxel vs docetaxel in metastatic hormone-naïve prostate cancer (clinical trial protocol)', BJU International, 128, pp. 331 - 342, http://dx.doi.org/10.1111/bju.15384
,2021, 'Examining the ability of the Cancer and Aging Research Group tool to predict toxicity in older men receiving chemotherapy or androgen-receptor–targeted therapy for metastatic castration-resistant prostate cancer', Cancer, 127, pp. 2587 - 2594, http://dx.doi.org/10.1002/cncr.33523
,